Quorum Innovations
Quorum Innovations is a Sarasota-based microbiome biotherapeutics company that sells Qi601™, an FDA GRAS-designated postbiotic supplement that binds microplastics in the gut, directly to health-conscious consumers via its qi601.com e-commerce storefront.
- Company typePrivate
- Founded2011
- HeadquartersSarasota, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Quorum Innovations does
Quorum Innovations is a privately held microbiome biotherapeutics company headquartered in Sarasota, Florida, founded in 2011 by physician-scientists Dr. Nicholas Monsul and Dr. Eva Berkes. The company develops barrier-based microbiome technologies originating from two DARPA-funded research programs on protective biotherapeutics for military warfighters. Its flagship technology, the Biofilm Shield™, is a non-living, biofilm-derived postbiotic aggregate produced from heat-inactivated Lactobacillus fermentum (Qi6 strain), which has received FDA Generally Recognized as Safe designation under GRN 000988. The aggregate forms self-organizing macrostructures approximately 200 micrometers in diameter with a cobblestone-like surface topology that selectively binds micro- and nanoplastics in the gastrointestinal tract, reducing microplastic adherence to human intestinal epithelial cells by up to 83% in laboratory studies.
The company's commercial product, Qi601™, launched in 2025 and is sold directly to consumers as a once-daily oral postbiotic supplement via the proprietary e-commerce storefront qi601.com. Supporting technology platforms include the MiNE™ (Microbiome isolates and Novel Extracts) discovery engine and the Probiomic® biotherapeutic framework, both of which underpin the current product and a potential pipeline of additional barrier-defense candidates. The company holds over 55 issued patents across more than 50 countries and has active research collaborations with Bayer Pharmaceuticals in women's health, as well as participation in the HHS STOMP federal initiative on microplastics.
Quorum operates with 1–10 employees, sells only in the United States through direct-to-consumer channels, and generates revenue from one-time purchases and subscription orders of Qi601 capsules. Its business model is product-led and science-marketing-driven, emphasizing peer-reviewed clinical evidence, FDA GRAS status, and a patented mechanism of action rather than traditional retail distribution or institutional sales.
Quorum Innovations firmographics
Firmographics- Name
- Quorum Innovations
- Legal name
- Quorum Innovations
- Website
- https://quoruminnovations.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Quorum Innovations is a Sarasota-based microbiome biotherapeutics company that sells Qi601™, an FDA GRAS-designated postbiotic supplement that binds microplastics in the gut, directly to health-conscious consumers via its qi601.com e-commerce storefront.
- Ownership category
- akta.pro rank
Quorum Innovations industry classification
Industry- Product category
- Microbiome Therapeutics / Dietary Supplements
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Probiotics & Digestive Health Supplements (CRADAGAF)
- akta.pro secondary industry
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)
Keywords
Where Quorum Innovations is headquartered
LocationHeadquarters
- HQ city
- Sarasota
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Quorum Innovations business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Direct-to-Consumer Supplement Sales: Quorum generates revenue through direct sales of Qi601 capsules to consumers via its e-commerce platform at qi601.com. The product is sold as a daily oral supplement with pricing for individual bottles and potentially subscription options for recurring purchases.
- Consumer Direct Sales: One-time purchase of Qi601 supplement bottles through the company's e-commerce storefront, targeting health-conscious individual consumers concerned about microplastic exposure.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Quorum Innovations product offering
Product offeringCore offering
Quorum Innovations develops and sells Qi601™, the world's first microplastic detox supplement. Qi601 is a patented, orally administered, non-living postbiotic derived from heat-inactivated Lactobacillus fermentum that forms a biofilm-like matrix in the gastrointestinal tract to bind and sequester micro- and nanoplastics, preventing their absorption into the body. The product is sold direct-to-consumer through the company's own e-commerce platform at qi601.com, supported by the proprietary MiNE™ discovery platform and Probiomic® biotherapeutic technology framework with 55+ issued patents worldwide.
Product overview
Quorum Innovations develops microbiome biotherapeutics centered on its flagship product Qi601™ Biofilm Shield™ — a patented, orally administered postbiotic supplement that forms a non-systemic gut biofilm matrix to bind and sequester micro- and nanoplastics. The technology portfolio includes the MiNE™ (Microbiome isolates and Novel Extracts) discovery platform and the Probiomic® technology framework. Qi601™ represents the first commercial application, with the platform technologies supporting its development and enabling future biotherapeutic pipeline candidates for barrier defense applications.
Differentiator
Problem solved
Functional benefit
Brands
- Qi601: The world's first microplastic detox product - a patented, orally administered postbiotic derived from Lactobacillus fermentum that forms a biofilm shield to bind micro- and nanoplastics in the gut.
- MiNE™ Platform
- ProBiomic™
- Biofilm Shield™
Products and services
- Qi601™ Qi601™ is a patented, orally administered, non-living postbiotic derived from heat-inactivated Lactobacillus fermentum (GRN 000988) that forms self-aggregating biofilm macrostructures (~200 µm) in the gastrointestinal tract to physically bind and sequester micro- and nanoplastics, helping prevent their absorption into the human body. Sold direct-to-consumer through qi601.com as a once-daily capsule supplement.
Quantifiable outcome
- Up to 98% capture of nanoplastics in laboratory tests simulating digestive conditions
- +3 more outcomes
Companies that use Quorum Innovations
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Quorum Innovations technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Quorum Innovations partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- HHS STOMP InitiativecoreQuorum Innovations was invited to participate in the HHS STOMP (Strategic Training for Opioid Microplastics) initiative in Washington D.C., recognizing the company as a subject matter expert on microplastics and human health. The company joins federal leadership and key stakeholders working to address microplastic exposure impacts, positioning Quorum at the forefront of national public health efforts.
- Bayer PharmaceuticalscoreBayer Pharmaceuticals partnered with Quorum in a joint development program exploring biofilm barrier protection technologies for women's health applications in intimate care products. This collaboration validated the translational potential of Quorum's barrier defense platform beyond military applications.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Quorum Innovations competitors and assessment
Company assessmentDirect peers
- Seed Health: Seed is a science-led DTC microbiome company selling probiotic and synbiotic supplements with subscription e-commerce. Like Quorum, it markets clinically validated microbiome products directly to health-conscious consumers and emphasizes peer-reviewed research in its positioning.
- Pendulum Therapeutics: Pendulum develops microbiome-based interventions (notably Pendulum Glucose Control) and sells them DTC. It is a direct comparable to Quorum's model of translating microbiome science into consumer-facing products with clinical efficacy claims.
- Athletic Greens (AG1): AG1 is a high-growth DTC daily nutrition supplement brand with strong digital marketing and subscription economics. It shares Quorum's DTC e-commerce, subscription-based revenue model and health-conscious consumer positioning.
- Ritual: Ritual is a science-forward DTC supplement brand selling daily essentials with subscription e-commerce. It shares Quorum's emphasis on clinical validation, transparent ingredient sourcing, and direct-to-consumer distribution.
Broad incumbents
- Finch Therapeutics: Finch develops microbiome-based therapeutics with a focus on consortia-based drug products. It shares Quorum's microbiome therapeutics DNA but operates at a larger scale with a broader R&D pipeline and more established pharma partnerships.
- Align (Procter & Gamble): Align is a leading digestive health probiotic brand owned by Procter & Gamble. It targets the same health-conscious consumer seeking gut health benefits but at mass-market scale across food, drug, and mass retail channels.
- Culturelle (i-Health / Chr. Hansen): Culturelle is one of the largest clinically-backed probiotic supplement brands, owned by i-Health and now part of Chr. Hansen. It competes in the same digestive health probiotic category but with vastly broader retail distribution and brand recognition.
- Seres Therapeutics: Seres is a clinical-stage microbiome therapeutics company that has commercialized an FDA-approved microbiome therapy. It is broader in scope and more pharma-oriented than Quorum, but operates in the same microbiome therapeutics category.
Emerging players
- Symbiome: Symbiome is a microbiome-focused consumer brand founded by Larry Weiss, who serves as a Scientific Advisor to Quorum. It operates in the same adjacent microbiome consumer category and overlaps with Quorum's probiotic-derived technology positioning.
- AOBiome: AOBiome develops live bacterial therapeutics for skin and systemic conditions, with Larry Weiss serving as former CMO. It is an emerging microbiome therapeutics peer with overlapping scientific advisor relationships and a related biological approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Quorum Innovations social profiles
Digital presenceQuorum Innovations compliance and trust
Trust signalCompliance1 record
Quorum Innovations financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quorum Innovations leadership team
Management profileNumber of profiles
Profiles11 records
Quorum Innovations funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quorum Innovations M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quorum Innovations
What does Quorum Innovations do?
Quorum Innovations develops and sells Qi601™, the world's first microplastic detox supplement. Qi601 is a patented, orally administered, non-living postbiotic derived from heat-inactivated Lactobacillus fermentum that forms a biofilm-like matrix in the gastrointestinal tract to bind and sequester micro- and nanoplastics, preventing their absorption into the body. The product is sold direct-to-consumer through the company's own e-commerce platform at qi601.com, supported by the proprietary MiNE™ discovery platform and Probiomic® biotherapeutic technology framework with 55+ issued patents worldwide.
Is Quorum Innovations a public or private company?
Quorum Innovations is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Quorum Innovations founded?
Quorum Innovations was founded in 2011. It employs 1 to 10 people.
Where is Quorum Innovations based?
Quorum Innovations is headquartered in Sarasota, United States, in the North America region.
How does Quorum Innovations make money?
Two revenue lines are on record. Direct-to-Consumer Supplement Sales are the primary driver. The others are consumer Direct Sales.
Who are Quorum Innovations's main competitors?
Direct peers on record are Seed Health, Pendulum Therapeutics, Athletic Greens (AG1) and Ritual. Broad incumbents are Finch Therapeutics, Align (Procter & Gamble), Culturelle (i-Health / Chr. Hansen) and Seres Therapeutics. Emerging players are Symbiome and AOBiome.
Does Quorum Innovations have an API?
No public API is recorded for Quorum Innovations.
What industry is Quorum Innovations in?
Quorum Innovations's product category is Microbiome Therapeutics / Dietary Supplements. Its primary akta.pro industry code is CRADAGAF, Probiotics & Digestive Health Supplements, with a secondary code of HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits). Its NAICS code is 541714 and its SIC code is 2833.